Breaking Finance News

ProMetic Life Sciences (TSE:PLI) target price raised to $5.00, issued a report today by Scotia Capital

Yesterday ProMetic Life Sciences (TSE:PLI) traded -2.87% lower at $2.55. The company’s 50-day moving average is $2.83 and its 200-day moving average is $2.91. The last stock close price is down -18.61% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 1,796,985 shares of the stock were exchanged, up from an average trading volume of 1,533,610

ProMetic Life Sciences (TSE:PLI) had its target price raised to $5.00 by Scotia Capital in a report released 11/22/2016. The new target price indicates a possible upside of 0.96% based on the company's last stock close price.

Previously on 11/18/2016, Canaccord Genuity reported about ProMetic Life Sciences (TSE:PLI) raised the target price from $4.50 to $4.75. At the time, this indicated a possible upside of 0.68%.

See Chart Below

ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences has a 52 week low of $1.88 and a 52 week high of $3.62 The company’s market cap is currently $0.

Also covering ProMetic Life Sciences's price target, a total of 10 brokerages have released a report on ProMetic Life Sciences. The 12-month price target is $3.53 with two equity analysts rating the company a strong buy, eight brokers rating the stock a buy, 1 broker rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

Brief Synopsis On ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *